Quantum BioPharma is trading 5.42% higher at $2.80 in pre-market on October 15, versus its October 14 close of $2.66; available reports identified no clear company-specific catalyst. - The Phase 2 Lucid-MS trial agreement with Thermo Fisher and the company’s growth summit announcement were reported before October 15, so neither establishes a fresh overnight trigger. - Broader market signals were mixed and did not provide a clear same-direction explanation for the gain.